Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Annals of the Rheumatic Diseases
Journal
Overview
Identity
Overview
Publication Venue For
Circulating microbial small RNAs are altered in patients with rheumatoid arthritis
. 79:1557-1564.
2020
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
. 79:1400-1413.
2020
SARS CoV-2 infection among patients using immunomodulatory therapies.
2020
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry
. 79:859-866.
2020
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
. 79:S685-S699.
2020
Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery
. 79:573.
2020
Hypersensitivity reactions with allopurinol and febuxostat: A study using the Medicare claims data
. 79:529-535.
2020
Allopurinol versus febuxostat hypersensitivity reactions in the US elderly: Differences in study outcomes and populations. Response to: 'Correspondence to "hypersensitivity reactions with allopurinol and febuxostat: A study using the Medicare claims data' by Ma et al
2020
Declining in-hospital mortality gap between systemic lupus erythematosus (SLE) and non-SLE hospitalisations: A national study
2020
Hypersensitivity reactions with allopurinol versus febuxostat in the US elderly. Response to: 'Confunding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: A study using the Medicare claims data'' by Hsu et al
2020
Response to: Â &tild; Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease' by Sato et al
2020
Response to: € Cutaneous adverse events with febuxostat after previous reactions to allopurinol: Comment on the artcile by Singh and Clevland' by Quills et al
2020
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout
. 78:1592-1600.
2019
Response to: 'Clinical evidence guidelines in systemic lupus erythematosus: revaluation' by Scheinberg
. 78.
2019
Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39
. 78:1055-1061.
2019
Gout is associated with increased healthcare utilization after knee arthroplasty
. 78:1146-1148.
2019
Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort
. 78:1010-1012.
2019
Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis
. 78:355-364.
2019
Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis
. 78:355-364.
2019
Response to: 'Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?' by Suyama and Okada
. 78.
2019
Tapering Janus kinase inhibitors in rheumatoid arthritis with low disease activity or remission: Reality or dream?
. 78:153-154.
2019
Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis
2019
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis
. 78:1357-1362.
2019
Emergent high fatality lung disease in systemic juvenile arthritis
. 78:1722-1731.
2019
Neuropsychiatric events in systemic lupus erythematosus: A longitudinal analysis of outcomes in an international inception cohort using a multistate model approach
2019
Remission or low disease activity as a target in systemic lupus erythematosus
. 78.
2019
First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR)
. 77:1549-1557.
2018
Response to: 'Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults' by Lee and Song
. 77:e74.
2018
Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults
. 77:1243-1245.
2018
Response to: 'A response to singh. “Lesinurad combination therapy with allopurinol in gout: Do CLEAR studies make the treatment of gout clearer?”' by valiyil and schechter
. 77.
2018
Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors
. 77:1012-1016.
2018
Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids
. 77:644-649.
2018
EULAR gout treatment guidelines by Richette et al.: Uric acid and neurocognition
. 77.
2018
Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study
. 77:386-392.
2018
Role of serum urate in neurocognitive function and dementia: new evidence contradicts old thinking
. 77:317-318.
2018
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
. 76:1955-1964.
2017
Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL)
. 76:2071-2074.
2017
Weight loss for overweight and obese individuals with gout: A systematic review of longitudinal studies
. 76:1870-1882.
2017
Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: An analysis of Medicare claims data
. 76:1669-1678.
2017
Burden of musculoskeletal disorders in the Eastern Mediterranean Region, 1990-2013: Findings from the Global Burden of Disease Study 2013
. 76:1365-1373.
2017
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: Integrated analysis of data from the global clinical trials
. 76:1253-1262.
2017
Lesinurad combination therapy with allopurinol in gout: Do CLEAR studies make the treatment of gout clearer?
. 76:779-781.
2017
Chasing crystals out of the body: Will treat to serum urate target for gout help us get there?
. 76:629-631.
2017
Treat-To-Target (T2T) recommendations for gout
. 76:632-638.
2017
Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis
. 76:543-546.
2017
Allopurinol and the risk of atrial fibrillation in the elderly: A study using medicare data
. 76:72-78.
2017
Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure
. 76:133-139.
2017
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
. 76:960-977.
2017
Renal dosing of allopurinol results in suboptimal gout care
. 76.
2017
Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production
. 75:2007-2013.
2016
Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis
. 75:1813-1818.
2016
Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis
. 75:1757-1762.
2016
Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
. 75:1843-1847.
2016
Cervical cancer risk with the use of tumour necrosis factor inhibitors in rheumatoid arthritis: To worry or not to worry?
. 75:1265-1267.
2016
Tofacitinib, an oral Janus kinase inhibitor: Analysis of malignancies across the rheumatoid arthritis clinical development programme
. 75:831-841.
2016
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative
. 75:481-489.
2016
Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: Data from the National Veterans Health Administration
. 75:341-347.
2016
Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA
. 75:242-252.
2016
Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: Consensus recommendations for infection reporting during clinical trials and postmarketing surveillance
. 74:2107-2116.
2015
2015 Gout classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
. 74:1789-1798.
2015
A deletion at adamts9-magi1 locus is associated with psoriatic arthritis risk
. 74:1875-1881.
2015
Factors associated with damage accrual in patients with systemic lupus erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
. 74:1706-1713.
2015
Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: Data from an international inception cohort
. 74:1530-1536.
2015
Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology
. 74:963-969.
2015
Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: Persistent benefits. Data from the Corrona registry
. 74:1150-1155.
2015
Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy
. 74:1065-1071.
2015
The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: Data from a multiethnic Latin American cohort
. 74:1019-1023.
2015
Sensitivity and sensitisation in relation to pain severity in knee osteoarthritis: Trait or state?
. 74:682-688.
2015
When gout goes to the heart: Does gout equal a cardiovascular disease risk factor?
. 74:631-634.
2015
The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
. 74:430-436.
2015
Racial disparities in knee and hip total joint arthroplasty: An 18-year analysis of national medicare data
. 73:2107-2115.
2014
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: Results of the SAfety assessment of biologic ThERapy (SABER) study
. 73:1942-1948.
2014
A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab
. 73:1429-1430.
2014
Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid arthritis
. 73:785-786.
2014
The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis
. 73:1301-1308.
2014
Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist
. 72:1813-1818.
2013
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: Data from an international inception cohort
. 72:1308-1314.
2013
Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis
. 72:1375-1381.
2013
Serum urate association with hypertension in young adults: Analysis from the Coronary Artery Risk Development in Young Adults cohort
. 72:1321-1327.
2013
Co-localisation of non-cartilaginous articular pathology increases risk of cartilage loss in the tibiofemoral joint - The MOST study
. 72:942-948.
2013
Fine mapping of Xq28: Both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups
. 72:437-444.
2013
Low-dose prednisone chronotherapy for rheumatoid arthritis: A randomised clinical trial (CAPRA-2)
. 72:204-210.
2013
The role of varus and valgus alignment in the initial development of knee cartilage damage by MRI: The MOST study
. 72:235-240.
2013
Mycobacterial diseases and antitumour necrosis factor therapy in USA
. 72:37-42.
2013
Breaking the law of valgus: The surprising and unexplained prevalence of medial patellofemoral cartilage damage
. 71:1827-1832.
2012
Variation in the ICAM1-ICAM4-ICAM5 locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries
. 71:1809-1814.
2012
Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study
. 71:1502-1509.
2012
A role for PACE4 in osteoarthritis pain: Evidence from human genetic association and null mutant phenotype
. 71:1042-1048.
2012
Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study
. 71:924-928.
2012
Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus
. 71:694-699.
2012
Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at MSH5, HLA-DPB1 and HLA-G
. 71:777-784.
2012
IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus
. 71:463-468.
2012
Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: The ROSE study
. 71:198-205.
2012
Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: Exploratory analyses from the TEMPO trial
. 71:206-212.
2012
Cardiac and thromboembolic complications and mortality in patients undergoing total hip and total knee arthroplasty
. 70:2082-2088.
2011
Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus
. 70:1726-1732.
2011
Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus
. 70:1752-1757.
2011
Presence of MRI-detected joint effusion and synovitis increases the risk of cartilage loss in knees without osteoarthritis at 30-month follow-up: The MOST study
. 70:1804-1809.
2011
Risk factors for medial meniscal pathology on knee MRI in older US adults: A multicentre prospective cohort study
. 70:1733-1739.
2011
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents
. 70:1401-1406.
2011
Validation of pain and patient global scales in chronic gout: Data from two randomised controlled trials
. 70:1277-1281.
2011
SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus
. 70:961-967.
2011
Assessment of synovitis with contrast-enhanced MRI using a whole-joint semiquantitative scoring system in people with, or at high risk of, knee osteoarthritis: The MOST study
. 70:805-811.
2011
High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis
. 70:785-791.
2011
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis
. 70:576-582.
2011
US patients of hispanic and African ancestry develop lupus nephritis early in the disease course: Data from LUMINA, a multiethnic US cohort (LUMINA LXXIV)
. 70:393-394.
2011
An assessment of disease flare in patients with systemic lupus erythematosus: A comparison of BILAG 2004 and the flare version of SELENA
. 70:54-59.
2011
Explaining the cardiovascular risk associated with rheumatoid arthritis: Traditional risk factors versus markers of rheumatoid arthritis severity
. 69:1920-1925.
2010
Serum urate and its relationship with alcoholic beverage intake in men and women: Findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort
. 69:1965-1970.
2010
Varus and valgus alignment and incident and progressive knee osteoarthritis
. 69:1940-1945.
2010
Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis
. 69:1612-1617.
2010
From bone biology to clinical outcome: State of the art and future perspectives
. 69:1415-1419.
2010
ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry
. 69:1329-1332.
2010
Patient and rheumatologist perspectives on glucocorticoids: An exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
. 69:1015-1021.
2010
Subchondral bone attrition may be a reflection of compartment-specific mechanical load: The MOST Study
. 69:841-844.
2010
Genetic variants of STAT4 associated with rheumatoid arthritis in persons of Asian and European ancestry do not replicate in African Americans
. 69:625-626.
2010
The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases
. 69:696-699.
2010
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus
. 69:529-535.
2010
Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide
. 69:43-47.
2010
High systemic bone mineral density increases the risk of incident knee OA and joint space narrowing, but not radiographic progression of existing knee OA: The MOST study
. 69:163-168.
2010
Meniscal pathology on MRI increases the risk for both incident and enlarging subchondral bone marrow lesions of the knee: The MOST study
. 69:1796-1802.
2010
Relation of synovitis to knee pain using contrast-enhanced MRIs
. 69:1779-1783.
2010
Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases
. 68:1800-1804.
2009
Change in MRI-detected subchondral bone marrow lesions is associated with cartilage loss: The MOST Study. A longitudinal multicentre study of knee osteoarthritis
. 68:1461-1465.
2009
Opportunities for improving medication use and monitoring in gout
. 68:1265-1270.
2009
Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus
. 67:1724-1731.
2008
Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis
. 67:1529-1534.
2008
Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not?
. 67:1358-1359.
2008
Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells
. 67:1488-1492.
2008
Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans
. 67:1310-1316.
2008
Predictors of premature gonadal failure in patients with systemic lupus erythematosus. Results from LUMINA, a multiethnic US cohort (LUMINA LVIII)
. 67:1170-1173.
2008
A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout
. 67:888-891.
2008
Seizures in patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic cohort (LUMINA LIV)
. 67:829-834.
2008
Systemic lupus erythaematosus in a multiethnic US cohort (LUMINA) LIII: Disease expression and outcome in acute onset lupus
. 67:500-504.
2008
The relationship between cancer and medication exposures in systemic lupus erythaematosus: A case-cohort study
. 67:74-79.
2008
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
. 66:1560-1567.
2007
Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA L)
. 66:1168-1172.
2007
African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: Results from LUMINA, a multiethnic cohort (LUMINAXLV)
. 66:618-622.
2007
Systemic lupus erythematosus in a multiethnic US cohort LUMINA (XLI): Factors predictive of self-reported work disability
. 66:12-17.
2007
Sex differences in gout epidemiology: Evaluation and treatment
. 65:1368-1372.
2006
Racial or ethnic differences in allele frequencies of sinqle-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis
. 65:1213-1218.
2006
Smoking interacts with genetic risk factors in the development of rheumatoid arthritis among older Caucasian women
. 65:1163-1167.
2006
Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time
. 65:1168-1174.
2006
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: Results of a nested matched case-control study
. 65:785-790.
2006
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data
. 65:285-293.
2006
Correlation of serum B lymphocyte stimulator and β
2
microglobulin with autoantibody secretion and systemic involvement in primary Sjögren's syndrome
. 64:1050-1055.
2005
Gout epidemiology: Results from the UK General Practice Research Database, 1990-1999
. 64:267-272.
2005
Immunohistochemistry of normal synovium [2] (multiple letters)
. 63:1532-1533.
2004
Immunohistochemistry of normal human knee synovium: A quantitative study
. 63:785-790.
2004
Increased DNA fragmentation and ultrastructural changes in fibromyalgic muscle fibres
. 63:245-251.
2004
Glucocorticoids in the treatment of early and late RA
. 62:1033-1037.
2003
Polymicrobial septic arthritis in a patient with Wilson's disease [12]
. 62:693-694.
2003
The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome
. 62:168-171.
2003
Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: Results from the Iowa Women's Health Study
. 61:994-999.
2002
Cigarette smoking and rheumatoid arthritis severity
. 56:463-469.
1997
Rheumatoid arthritis preceding the onset of polyarticular tophaceous gout.
. 55:489-490.
1996
Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients
. 54:708-712.
1995
Folate supplementation and methotrexate [3]
. 52:315-316.
1993
Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: Two cellular mechanisms explain joint destruction?
. 52.
1993
Controlled trial of methotrexate versus 10-deazaaminopterin in the treatment of rheumatoid arthritis
. 51:600-603.
1992
False positive results for antibody to HIV in two men with systemic lupus erythematosus
. 51:1071-1073.
1992
Local immune responses in certain extra-articular manifestations of rheumatoid arthritis
. 51:698-701.
1992
5-Fluorouracil in the treatment of scleroderma: A randomised, double blind, placebo controlled international collaborative study
. 49:926-928.
1990
Osteoarthritis: Definitions and criteria
. 49:201.
1990
Auricular chondritis and diffuse proliferative glomerulonephritis in primary Sjögren's syndrome
. 48:683-685.
1989
Pulmonary hypertension in primary Sjogren's syndrome
. 47:251-253.
1988
Sarcoidosis presenting as antinuclear antibody positive glomerulonephritis
. 47:337-339.
1988
Brucellar arthritis: A study of 39 Peruvian families
. 46:506-509.
1987
A new promising treatment in systemic sclerosis: 5-fluorouracil
. 46:763-767.
1987
Rheumatic manifestations of brucellosis.
. 45:526.
1986
Tissue typing in brucellosis.
. 45:351.
1986
Multiple microcrystal deposition disease in a patient with systemic lupus erythematosus
. 43:498-502.
1984
Identity
International Standard Serial Number (issn)
0003-4967
Electronic International Standard Serial Number (eissn)
1468-2060